Targeted treatment of liver metastasis from gastric cancer using specific binding peptide

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Gastric cancer is a leading cause of cancer death in China, with liver metastasis being a primary driver.
• Targeting cytokines like Tumor Necrosis Factor (TNF) is a strategy for cancer gene therapy.
• Developing effective treatments for gastric cancer liver metastasis remains a critical challenge.

Purpose of the Study:

• To create a novel fusion protein targeting gastric cancer cells with high liver metastasis potential.
• To evaluate the efficacy of the pd20-TNF fusion protein in vitro and in vivo.
• To explore new therapeutic strategies for advanced gastric cancer liver metastasis.

Main Methods:

• DNA recombinant techniques were used to fuse the gastric cancer-specific binding peptide pd20 with human TNF.
• The fusion protein's expression was induced, and the protein was purified.
• In vitro activity tests and tumor implantation experiments in nude mice were conducted.

Main Results:

• The pd20-TNF fusion protein demonstrated enhanced membrane permeability of liver cells in mice with gastric cancer liver metastasis.
• Tumor implantation experiments showed significant mitigation of cancer lesions in nude mice treated with the fusion protein.
• The study provides evidence for the potential of pd20-TNF as a targeted therapeutic agent.

Conclusions:

• The pd20-TNF fusion protein shows promise for targeted therapy against gastric cancer liver metastasis.
• This approach may offer a new strategy for treating advanced gastric cancer with liver involvement.
• Further research is warranted to translate these findings into clinical applications for gastric cancer patients.